Assessment of <i>in vitro</i> inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes

Chavan, Rajesh; Zope, Vineet; Chavan, Nilesh; Shaikh, Javeed; Patil, Kiran R.; Yeole, Ravindra; Bhagwat, Sachin; Patel, Mahesh

doi:10.1080/00498254.2020.1756007

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, nemonoxacin was not associated with severe AEs, such as phototoxicity, hepatotoxicity, or severe CNS effects. 124,125 Furthermore, a systematic review and meta-analysis suggested that nemonoxacin might be safer than levofloxacin regarding cardiotoxicity. 126 Another phase 3 RCT comparing the IV formulation of nemonoxacin to levofloxacin in moderate-to-severe CAP patients (PSI classes II-IV) has been completed, and publication is expected (NCT02205112).…”

Section: New Generation Fluoroquinolones (Delafloxacin and Nemonoxacin)mentioning

confidence: 99%

Antibiotic Strategies for Severe Community-Acquired Pneumonia

Bassetti,

Giacobbe,

Magnasco

et al. 2024

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Despite advancements in health systems and intensive care unit (ICU) care, along with the introduction of novel antibiotics and microbiologic techniques, mortality rates in severe community-acquired pneumonia (sCAP) patients have not shown significant improvement. Delayed admission to the ICU is a major risk factor for higher mortality. Apart from choosing the appropriate site of care, prompt and appropriate antibiotic therapy significantly affects the prognosis of sCAP. Treatment regimens involving ceftaroline or ceftobiprole are currently considered the best options for managing patients with sCAP. Additionally, several other molecules, such as delafloxacin, lefamulin, and omadacycline, hold promise as therapeutic strategies for sCAP. This review aims to provide a comprehensive summary of the key challenges in managing adults with severe CAP, focusing on essential aspects related to antibiotic treatment and investigating potential strategies to enhance clinical outcomes in sCAP patients.

show abstract

Section: New Generation Fluoroquinolones (Delafloxacin and Nemonoxacin)mentioning

confidence: 99%

Antibiotic Strategies for Severe Community-Acquired Pneumonia

Bassetti,

Giacobbe,

Magnasco

et al. 2024

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…Parenteral administration, as well as the oral administration of its prodrug (WCK-2349 (alalevonadifloxacin)), are being evaluated for the treatment of acute bacterial infections of the skin and skin structure (ABSSSI) as well as for respiratory diseases such as community-acquired bacterial pneumonia (CABP) and hospital-acquired bacterial pneumonia (HABP) [ 17 ]. These drugs are active against several pathogens including methicillin-resistant Staphylococcus aureus (MRSA) [ 16 ]; they were recently approved in India for ABSSSI based on a completed Phase III trial [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?

2021

View full text Add to dashboard Cite

Carbapenem-resistant Acinetobacter baumannii has been classified as a top priority for the development of new therapies due to its resistance to most antibiotics. Drug repurposing may be a fast and inexpensive strategy for treating this pathogen. This review aims to critically evaluate repurposed drugs for the treatment of infections caused by carbapenem-resistant A. baumannii , correlating their antimicrobial activity with data available for toxicity and side effects. Some drugs have been suggested as promising candidates for repurposing; however, in some cases, high toxicity and low plasma concentrations reduce applicability in clinical practice. The most favorable applicability is offered by fusidic acid and colistin, possibly combined with a third agent, promising to be well tolerated and achieving satisfactory plasma concentrations.

show abstract